?
?
?
Harbin Sanlian laid out the veterinary drug market, built projects such as maduramicin ammonium, monensin raw materials premixes. 2023-01-12
Yunnan Zewei Pharmaceutical Co., Ltd. Reconstruction expansion project of steroid hormone raw materials (progesterone, BA, methylprednisolone, difucol, etc.) 2023-01-12
Anhui Baker Pharmaceutical Co., Ltd. newly built Monapinavir Lopinavir API project 2023-01-12
The net profit of East Asia pharmaceutical industry in 2022 was 104 million yuan, the production sales of 7-ANCA increased significantly. 2023-01-12
Anhui Fengyuan Likang Pharmaceutical invested in rebuilding the new valine project. 2023-01-12
Announcement of commissioning time of isosorbide project of Shandong Tianli Pharmaceutical Co., Ltd. (as of March 31, 2023) 2023-01-12
Shandong Xiaowei Biotechnology invested in a new project of bio-fermentation to produce bio-based L- malic acid succinic acid. 2023-01-12
Yunnan Zewei Pharmaceutical Co., Ltd. expands the project of steroid hormone raw materials, namely, diprogesterone, vitamin D3, vitamin D2 nicotine. 2023-01-12
With a total investment of 620 million yuan, Yunnan Pingbian natural astaxanthin big health industry integration development project started construction. 2023-01-12
BASFs expanded propionic acid production capacity will be put into production in the fourth quarter of 2023. 2023-01-12
Anhui Huaheng Biological Company launched a new product "inositol" 2023-01-06
Inner Mongolia Jindawei Pharmaceutical Co., Ltd. rebuilt expanded new projects such as adenosylmethionine, glutathione phosphatidylserine. 2023-01-06
Hendi Pharmaceutical Industry: At present, the companys production capacity of ibuprofen is 3500 tons/year. 2022-12-30
Jiheng Pharmaceutical Co., Ltd.: Paracetamol raw materials are suspended for export are all supplied to China. 2022-12-30
Guo Bang Pharmaceutical Co., Ltd. expanded its technical transformation project with an annual output of 1,171 tons of raw materials intermediates (Norfloxacin, etc.) 2022-12-30
The latest quotation of main products (vitamin B12, coenzyme Q10, etc.) of Yuxing Biological Group on December 29th 2022-12-30
Haocheng Bio invested 150 million yuan to build a new lactose peptide, protein powder inositol project (Phase I). 2022-12-30
Jiangxi Haiwen Biotechnology Co., Ltd. invested in a new project with an annual output of 10,000 tons of vitamin B3. 2022-12-30
Latest news: NHU Vitamin E production line will be discontinued from January 1, 2023. 2022-12-30
Brother Haining Vitamin K3 Base of Science Technology plans to stop production overhaul at the end of December 2022. 2022-12-30
Four major vitamin K3 enterprises in China announced the end of the year to stop production overhaul. 2022-12-30
Latest news: Amoxicillin Ampicillin API manufacturers raise their external prices. 2022-12-16
Brother Haining Vitamin K3 Base of Science Technology plans to stop production overhaul at the end of December 2022. 2022-12-15
The vitamin C production line of DSM Jiangshan Pharmaceutical will be reduced from December 5th. 2022-12-08
The demfor cold medicines has increased greatly, the crude drugs of antipyretic analgesic drugs are tight expensive. 2022-11-27
DSM is affected by the energy cost, the production base of vitamin A will stop production. 2022-11-27
DSM recently issued a notice on the discontinuation of vitamin A the reduction of vitamin E production. 2022-11-27
Sichuan Bohaodas 10,000-ton enzymatic inositol production line project will be completed by the end of 2022. 2022-11-27
Some manufacturers stopped reporting signing vitamin A vitamin E from November 23rd until the end of the year. 2022-11-27
On November 23rd, the quotation of NHU Vitamin E products was suspended. 2022-11-27
Novo Nordisk Shanghai ShanghaiPharmaceutical Holdings sign a contract to make another breakthrough incooperation 2022-11-17
Hebei Guangxiang Pharmaceutical Co., Ltd. has a busy production line, it is estimated that the export volume will break 100 million USD in 2022. 2022-11-15
¹²
4273 ¸ö Ò³´Î:
1 /
134 Ò³
32 ¸ö/Ò³
Ê×Ò³ ÉÏÒ»Ò³ ÏÂÒ»Ò³ βҳ
תµ½£º
µÚ1Ò³
µÚ2Ò³
µÚ3Ò³
µÚ4Ò³
µÚ5Ò³
µÚ6Ò³
µÚ7Ò³
µÚ8Ò³
µÚ9Ò³
µÚ10Ò³
µÚ11Ò³
µÚ12Ò³
µÚ13Ò³
µÚ14Ò³
µÚ15Ò³
µÚ16Ò³
µÚ17Ò³
µÚ18Ò³
µÚ19Ò³
µÚ20Ò³
µÚ21Ò³
µÚ22Ò³
µÚ23Ò³
µÚ24Ò³
µÚ25Ò³
µÚ26Ò³
µÚ27Ò³
µÚ28Ò³
µÚ29Ò³
µÚ30Ò³
µÚ31Ò³
µÚ32Ò³
µÚ33Ò³
µÚ34Ò³
µÚ35Ò³
µÚ36Ò³
µÚ37Ò³
µÚ38Ò³
µÚ39Ò³
µÚ40Ò³
µÚ41Ò³
µÚ42Ò³
µÚ43Ò³
µÚ44Ò³
µÚ45Ò³
µÚ46Ò³
µÚ47Ò³
µÚ48Ò³
µÚ49Ò³
µÚ50Ò³
µÚ51Ò³
µÚ52Ò³
µÚ53Ò³
µÚ54Ò³
µÚ55Ò³
µÚ56Ò³
µÚ57Ò³
µÚ58Ò³
µÚ59Ò³
µÚ60Ò³
µÚ61Ò³
µÚ62Ò³
µÚ63Ò³
µÚ64Ò³
µÚ65Ò³
µÚ66Ò³
µÚ67Ò³
µÚ68Ò³
µÚ69Ò³
µÚ70Ò³
µÚ71Ò³
µÚ72Ò³
µÚ73Ò³
µÚ74Ò³
µÚ75Ò³
µÚ76Ò³
µÚ77Ò³
µÚ78Ò³
µÚ79Ò³
µÚ80Ò³
µÚ81Ò³
µÚ82Ò³
µÚ83Ò³
µÚ84Ò³
µÚ85Ò³
µÚ86Ò³
µÚ87Ò³
µÚ88Ò³
µÚ89Ò³
µÚ90Ò³
µÚ91Ò³
µÚ92Ò³
µÚ93Ò³
µÚ94Ò³
µÚ95Ò³
µÚ96Ò³
µÚ97Ò³
µÚ98Ò³
µÚ99Ò³
µÚ100Ò³
µÚ101Ò³
µÚ102Ò³
µÚ103Ò³
µÚ104Ò³
µÚ105Ò³
µÚ106Ò³
µÚ107Ò³
µÚ108Ò³
µÚ109Ò³
µÚ110Ò³
µÚ111Ò³
µÚ112Ò³
µÚ113Ò³
µÚ114Ò³
µÚ115Ò³
µÚ116Ò³
µÚ117Ò³
µÚ118Ò³
µÚ119Ò³
µÚ120Ò³
µÚ121Ò³
µÚ122Ò³
µÚ123Ò³
µÚ124Ò³
µÚ125Ò³
µÚ126Ò³
µÚ127Ò³
µÚ128Ò³
µÚ129Ò³
µÚ130Ò³
µÚ131Ò³
µÚ132Ò³
µÚ133Ò³
µÚ134Ò³
Our Advantages of Reports
¢ÙAll reports written by ourselves
Purchase Flow of Reports
¢ÙConfirm purchase (If necessary sign the contract)
Bank account
¢ÙBeneficiary's Name:Beijing orientbit technology ltd
News 
